Why natural killer cells in triple negative breast cancer?
作者机构：Biotechnology ProgramFaculty of Pharmacy and BiotechnologyGerman University in CairoCairo 11835Egypt Pharmaceutical Biology DepartmentFaculty of Pharmacy and BiotechnologyGerman University in CairoCairo 11835Egypt
出 版 物：《World Journal of Clinical Oncology》 (世界临床肿瘤学杂志（英文版）)
年 卷 期：2020年第11卷第7期
页 面：464-476页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Triple negative breast cancer Natural killer cells Immune checkpoint blockades Programmed death-ligand 1 Cytotoxic T-lymphocyte-associated protein 4 Natural killer lectin-like group 2 member D
摘 要：The triple-negative subtype of breast cancer(TNBC)has the bleakest prognosis,owing to its lack of either hormone receptor as well as human epidermal growth factor receptor ***,immunotherapy has emerged as the front-runner for TNBC treatment,which avoids potentially damaging ***,despite its documented association with aggressive side effects and developed resistance,immune checkpoint blockade continues to dominate the TNBC immunotherapy *** immune checkpoint blockade drawbacks necessitate the exploration of other immunotherapeutic methods that would expand options for TNBC *** such method is the exploitation and recruitment of natural killer cells,which by harnessing the innate rather than adaptive immune system could potentially circumvent the downsides of immune checkpoint *** this review,the authors will elucidate the advantageousness of natural killer cell-based immuno-oncology in TNBC as well as demonstrate the need to more extensively research such therapies in the future.
维普期刊数据库